1Division of Infectious Disease Response, Chungnam Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, Daejeon, Republic of Korea
2Chungnam Center for Infectious Diseases Control and Prevention, Hongseong, Republic of Korea
3Division of Infectious Disease Control, Bureau of Infectious Disease Policy, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea
© 2023 Korea Disease Control and Prevention Agency.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ethics Approval
Obtaining informed consent was exempted by the IRB of Korea Disease Control and Prevention Agency (IRB No: 2021-11-08-PE-A) as there was no personal information in the study.
Conflicts of Interest
The authors have no conflicts of interest to declare.
Funding
None.
Availability of Data
The datasets are not publicly available but are available from the corresponding author upon reasonable request.
Authors’ Contributions
Conceptualization: BIK; Data curation: JS; Formal analysis: JS; Methodology: EL, YC; Project administration: BIK; Resources: JS, GK; Visualization: JS, EK; Writing–original draft: JS, Writing–review & editing: all authors.
Additional Information
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Korea Disease Control and Prevention Agency or the institutions with which the authors are affiliated.
Characteristic | Total | Infected | Uninfected | Attack rate (%) | p-valuea) | ||
---|---|---|---|---|---|---|---|
Total | 602 (100.0) | 434 (100.0) | 168 (100.0) | 72.1 | |||
Sex | <0.001 | ||||||
Male | 240 (39.9) | 155 (35.7) | 85 (50.6) | 64.6 | |||
Female | 362 (60.1) | 279 (64.3) | 83 (49.4) | 77.1 | |||
Age (y) | 0.002 | ||||||
≤59 | 372 (61.8) | 252 (58.1) | 120 (71.4) | 67.7 | |||
60–69 | 129 (21.4) | 108 (24.9) | 21 (12.5) | 83.7 | |||
≥70 | 101 (16.8) | 74 (17.1) | 27 (16.1) | 73.3 | |||
Employment (n=429)b) | <0.001 | ||||||
No | 266 (62.0) | 266 (65.8) | 0 (0.0) | 100 | |||
Yes | 163 (38.0) | 138 (34.2) | 25 (100.0) | 84.7 | |||
Residence (n=466)c) | <0.001 | ||||||
<500 m | 220 (47.2) | 193 (52.7) | 27 (27.0) | 87.7 | |||
500–1,000 m | 208 (44.6) | 151 (41.3) | 57 (57.0) | 72.6 | |||
>1,000 m | 38 (8.2) | 22 (6.0) | 16 (16.0) | 57.9 | |||
Vaccination status | <0.001 | ||||||
Unvaccinated | 458 (76.1) | 374 (86.2) | 84 (50.0) | 81.7 | |||
1 dose | 9 (1.5) | 5 (1.2) | 4 (2.4) | 55.6 | |||
2 doses | 135 (22.4) | 55 (12.7) | 80 (47.6) | 40.7 | |||
Data are presented as n (%).
a)Determined using the chi-square test, unless otherwise specified.
b)People whose occupation was not confirmed were excluded (n=173).
c)Registered people in other regions were excluded based on their residence listed in the resident registration (n=136). Residence: distance from religious facilities.
Characteristic | n (%) | aORb) | 95% CI | p-value |
---|---|---|---|---|
Sex | 434 (100.0) | |||
Male | 155 (35.7) | Reference | 0.78–2.18 | 0.308 |
Female | 279 (64.3) | 1.31 | ||
Age (y) | 434 (100.0) | |||
≤59 | 252 (58.1) | Reference | ||
60-69 | 108 (24.9) | 6.23 | 2.66–14.59 | <0.001 |
≥70 | 74 (17.1) | 2.89 | 1.36–6.16 | 0.006 |
Residence (n=366)a) | 366 (100.0) | |||
<500 m | 193 (52.7) | 3.42 | 1.42–8.21 | 0.006 |
500–1,000 m | 151 (41.3) | 1.47 | 0.64–3.38 | 0.364 |
>1,000 m | 22 (6.0) | Reference | ||
Vaccination status | 434 (100.0) | |||
Unvaccinated | 374 (86.2) | 9.23 | 5.03–16.93 | <0.001 |
Vaccinated | 60 (13.8) | Reference |
aOR, adjusted odds ratio; CI, confidence interval.
a)Registered people in other regions were excluded based on their residence listed in the resident registration (n=68). Residence: distance from religious facilities.
b)Odds ratios were calculated by logistic regression after adjustment for sex, age, residence, and vaccination state.
Vaccination status | Total (n=602) | Infected (n=434) | VE (95% CI) | |||
---|---|---|---|---|---|---|
Unvaccinated | Vaccinateda) | Unvaccinated | Vaccinated | |||
Sex | 458 (76.1) | 144 (23.9) | 374 (86.2) | 60 (13.8) | 49.0 (37.8–58.1) | |
Male | 164 (68.3) | 76 (31.7) | 123 (79.4) | 32 (20.6) | 43.9 (25.9–57.5) | |
Female | 294 (81.2) | 68 (18.8) | 251 (90.0) | 28 (10.0) | 51.8 (35.7–63.8) | |
Age (y) | 458 (76.1) | 144 (23.9) | 374 (86.2) | 60 (13.8) | 49.0 (37.8–58.1) | |
≤59 | 307 (82.5) | 65 (17.5) | 235 (93.3) | 17 (6.7) | 65.8 (48.3–77.4) | |
60–69 | 86 (66.7) | 43 (33.3) | 83 (76.9) | 25 (23.1) | 39.8 (22.1–53.4) | |
≥70 | 65 (64.4) | 36 (35.6) | 56 (75.7) | 18 (24.3) | 42.0 (18.4–58.7) | |
Occupationb) | 361 (84.1) | 68 (15.9) | 349 (86.4) | 55 (13.6) | 16.3 (5.9–25.6) | |
No | 228 (85.7) | 38 (14.3) | 228 (85.7) | 38 (14.3) | - | |
Yes | 133 (81.6) | 30 (18.4) | 121 (87.7) | 17 (12.3) | 37.7 (14.4–54.7) | |
Residencec) | 373 (80.0) | 93 (20.0) | 321 (87.7) | 45 (12.3) | 43.8 (30.4–46.0) | |
<500 m | 186 (84.5) | 34 (15.5) | 166 (86.0) | 27 (14.0) | 11.0 (-63.0–25.5) | |
500–1,000 m | 162 (77.9) | 46 (22.1) | 136 (90.1) | 15 (9.9.) | 61.2 (42.8–74.4) | |
>1,000 m | 25 (65.8) | 13 (34.2) | 19 (86.4) | 3 (13.6) | 69.6 (16.1–89.0) |
aOR, adjusted odds ratio; CI, confidence interval.
a)Vaccinated: Those for whom 14 days had passed since receiving the second dose.
b)People whose occupation was not confirmed were excluded (n=173).
c)Registered people in other regions were excluded based on their residence listed in the resident registration (n=136). Residence: distance from the religious facilities.
Characteristic | Total | Infected | Uninfected | Attack rate (%) | p-value |
||
---|---|---|---|---|---|---|---|
Total | 602 (100.0) | 434 (100.0) | 168 (100.0) | 72.1 | |||
Sex | <0.001 | ||||||
Male | 240 (39.9) | 155 (35.7) | 85 (50.6) | 64.6 | |||
Female | 362 (60.1) | 279 (64.3) | 83 (49.4) | 77.1 | |||
Age (y) | 0.002 | ||||||
≤59 | 372 (61.8) | 252 (58.1) | 120 (71.4) | 67.7 | |||
60–69 | 129 (21.4) | 108 (24.9) | 21 (12.5) | 83.7 | |||
≥70 | 101 (16.8) | 74 (17.1) | 27 (16.1) | 73.3 | |||
Employment (n=429) |
<0.001 | ||||||
No | 266 (62.0) | 266 (65.8) | 0 (0.0) | 100 | |||
Yes | 163 (38.0) | 138 (34.2) | 25 (100.0) | 84.7 | |||
Residence (n=466) |
<0.001 | ||||||
<500 m | 220 (47.2) | 193 (52.7) | 27 (27.0) | 87.7 | |||
500–1,000 m | 208 (44.6) | 151 (41.3) | 57 (57.0) | 72.6 | |||
>1,000 m | 38 (8.2) | 22 (6.0) | 16 (16.0) | 57.9 | |||
Vaccination status | <0.001 | ||||||
Unvaccinated | 458 (76.1) | 374 (86.2) | 84 (50.0) | 81.7 | |||
1 dose | 9 (1.5) | 5 (1.2) | 4 (2.4) | 55.6 | |||
2 doses | 135 (22.4) | 55 (12.7) | 80 (47.6) | 40.7 | |||
Characteristic | n (%) | aORb) | 95% CI | p-value |
---|---|---|---|---|
Sex | 434 (100.0) | |||
Male | 155 (35.7) | Reference | 0.78–2.18 | 0.308 |
Female | 279 (64.3) | 1.31 | ||
Age (y) | 434 (100.0) | |||
≤59 | 252 (58.1) | Reference | ||
60-69 | 108 (24.9) | 6.23 | 2.66–14.59 | <0.001 |
≥70 | 74 (17.1) | 2.89 | 1.36–6.16 | 0.006 |
Residence (n=366) |
366 (100.0) | |||
<500 m | 193 (52.7) | 3.42 | 1.42–8.21 | 0.006 |
500–1,000 m | 151 (41.3) | 1.47 | 0.64–3.38 | 0.364 |
>1,000 m | 22 (6.0) | Reference | ||
Vaccination status | 434 (100.0) | |||
Unvaccinated | 374 (86.2) | 9.23 | 5.03–16.93 | <0.001 |
Vaccinated | 60 (13.8) | Reference |
Vaccination status | Total (n=602) | Infected (n=434) | VE (95% CI) | |||
---|---|---|---|---|---|---|
Unvaccinated | Vaccinated |
Unvaccinated | Vaccinated | |||
Sex | 458 (76.1) | 144 (23.9) | 374 (86.2) | 60 (13.8) | 49.0 (37.8–58.1) | |
Male | 164 (68.3) | 76 (31.7) | 123 (79.4) | 32 (20.6) | 43.9 (25.9–57.5) | |
Female | 294 (81.2) | 68 (18.8) | 251 (90.0) | 28 (10.0) | 51.8 (35.7–63.8) | |
Age (y) | 458 (76.1) | 144 (23.9) | 374 (86.2) | 60 (13.8) | 49.0 (37.8–58.1) | |
≤59 | 307 (82.5) | 65 (17.5) | 235 (93.3) | 17 (6.7) | 65.8 (48.3–77.4) | |
60–69 | 86 (66.7) | 43 (33.3) | 83 (76.9) | 25 (23.1) | 39.8 (22.1–53.4) | |
≥70 | 65 (64.4) | 36 (35.6) | 56 (75.7) | 18 (24.3) | 42.0 (18.4–58.7) | |
Occupation |
361 (84.1) | 68 (15.9) | 349 (86.4) | 55 (13.6) | 16.3 (5.9–25.6) | |
No | 228 (85.7) | 38 (14.3) | 228 (85.7) | 38 (14.3) | - | |
Yes | 133 (81.6) | 30 (18.4) | 121 (87.7) | 17 (12.3) | 37.7 (14.4–54.7) | |
Residence |
373 (80.0) | 93 (20.0) | 321 (87.7) | 45 (12.3) | 43.8 (30.4–46.0) | |
<500 m | 186 (84.5) | 34 (15.5) | 166 (86.0) | 27 (14.0) | 11.0 (-63.0–25.5) | |
500–1,000 m | 162 (77.9) | 46 (22.1) | 136 (90.1) | 15 (9.9.) | 61.2 (42.8–74.4) | |
>1,000 m | 25 (65.8) | 13 (34.2) | 19 (86.4) | 3 (13.6) | 69.6 (16.1–89.0) |
Data are presented as Determined using the chi-square test, unless otherwise specified. People whose occupation was not confirmed were excluded ( Registered people in other regions were excluded based on their residence listed in the resident registration (
aOR, adjusted odds ratio; CI, confidence interval. Registered people in other regions were excluded based on their residence listed in the resident registration ( Odds ratios were calculated by logistic regression after adjustment for sex, age, residence, and vaccination state.
aOR, adjusted odds ratio; CI, confidence interval. Vaccinated: Those for whom 14 days had passed since receiving the second dose. People whose occupation was not confirmed were excluded ( Registered people in other regions were excluded based on their residence listed in the resident registration (